未知生产厂商
PCLX-001 is a first-in-kind N-Myristoyltransferase (NMT) inhibitor being developed by Pacylex Pharmaceuticals. Current studies have shown that PCLX-001 works differently than other known cancer drugs and has high activity and positive results in breast, lung, bladder and pancreas cancers.
PCLX-001 is a first-in-kind N-Myristoyltransferase (NMT) inhibitor being developed by Pacylex Pharmaceuticals. Current studies have shown that PCLX-001 works differently than other known cancer drugs and has high activity and positive results in breast, lung, bladder and pancreas cancers.
